Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 47Genitourinary 43Other hematologic neoplasm 12Plasma cell 7Myeloid 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Prednisone × Gynecologic × Clear all
NCT04726332 2024-05-14

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Exelixis

Phase 1 Terminated
52 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡